Cargando…

The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era

The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zheng, Hu, Yue, Zeng, Ming, Hu, Qinyong, Ye, Fei, Liu, Ruifeng, Cai, Hongyi, Li, Qiang, Wang, Xiaohu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516283/
https://www.ncbi.nlm.nih.gov/pubmed/36185295
http://dx.doi.org/10.3389/fonc.2022.976143
_version_ 1784798674117722112
author Li, Zheng
Hu, Yue
Zeng, Ming
Hu, Qinyong
Ye, Fei
Liu, Ruifeng
Cai, Hongyi
Li, Qiang
Wang, Xiaohu
author_facet Li, Zheng
Hu, Yue
Zeng, Ming
Hu, Qinyong
Ye, Fei
Liu, Ruifeng
Cai, Hongyi
Li, Qiang
Wang, Xiaohu
author_sort Li, Zheng
collection PubMed
description The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.
format Online
Article
Text
id pubmed-9516283
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95162832022-09-29 The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era Li, Zheng Hu, Yue Zeng, Ming Hu, Qinyong Ye, Fei Liu, Ruifeng Cai, Hongyi Li, Qiang Wang, Xiaohu Front Oncol Oncology The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9516283/ /pubmed/36185295 http://dx.doi.org/10.3389/fonc.2022.976143 Text en Copyright © 2022 Li, Hu, Zeng, Hu, Ye, Liu, Cai, Li and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Zheng
Hu, Yue
Zeng, Ming
Hu, Qinyong
Ye, Fei
Liu, Ruifeng
Cai, Hongyi
Li, Qiang
Wang, Xiaohu
The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title_full The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title_fullStr The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title_full_unstemmed The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title_short The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era
title_sort role transition of radiotherapy for the treatment of liver cancer in the covid-19 era
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516283/
https://www.ncbi.nlm.nih.gov/pubmed/36185295
http://dx.doi.org/10.3389/fonc.2022.976143
work_keys_str_mv AT lizheng theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT huyue theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT zengming theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT huqinyong theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT yefei theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT liuruifeng theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT caihongyi theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT liqiang theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT wangxiaohu theroletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT lizheng roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT huyue roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT zengming roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT huqinyong roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT yefei roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT liuruifeng roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT caihongyi roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT liqiang roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era
AT wangxiaohu roletransitionofradiotherapyforthetreatmentoflivercancerinthecovid19era